Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...
Newron Pharmaceuticals provides update following Type A meeting with the US FDA: Milan, Italy Saturday, July 4, 2026, 10:00 Hrs [IST] Newron Pharmaceuticals S.p.A. (Newron), a bio ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its ...
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a ...
The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
FutureG Office is investing in cutting-edge, next-gen techIt has handed $28m in funding to Cohere Technologies for the ...
You'll come for the hands-on tweaking and wealth of features, and quickly forgive some of the workflow issues when you hear ...
Despite the colloquially termed ‘fourth trimester’ having a clinical threshold of 6 to 12 weeks, growing evidence suggests that the postpartum period may extend for several months and, in some cases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results